bevacizumab (BP 01 / Bevqolva / BP01)

Dual therapy with Janus kinase inhibitors and biologics for atopic dermatitis: A systematic review.

Bai Jia Qi Adam JQA, Wen Sherilyn S, Chen Shuang S, Xu Yihang Y et al.

Targeted biologics in muscle strength restoration and corticosteroid sparing for patients post-myasthenic crisis.

Wang Yuan Y, Jin Lei L, Huan Xiao X, Chen Ran R et al.

Myasthenic crisis (MC) represents a life-threatening condition in patients with myasthenia gravis (MG). Despite a substantial reduction in in-hospital mortality for MC, full restoration of muscle strength and quality of life usually requires months or years. It remains unknown whether the sequential use of targeted biologics improves clinical outcomes in patients post-MC compared with the standard of care (SOC). We prospectively followed patients from MC through 6 months post-discharge between November 2018 and November 2025. We then stratified patients into subgroups according to the use of either biologics-based therapy (C5 inhibitors, FcRn antagonists, or rituximab) (BIO) or SOC. The primary endpoint was the Myasthenia Gravis Foundation of America-quantitative MG (MGFA-QMG) score at 6 months after discharge. Secondary outcomes included Myasthenia Gravis Activities of Daily Living (MG-ADL), steroid dose, immunosuppressant (IS) use, cumulative steroid exposure, minimal symptom expression (MSE), and residual symptom burden. At 6 months after discharge, the BIO group (n = 56) had a lower MGFA-QMG score than the SOC group (n = 56) (4.51 ± 4.03 vs 6.28 ± 4.72; P = 0.038). Meanwhile, the BIO group required a lower dose of oral corticosteroid (14.74 ± 10.24 vs 21.96 ± 12.87 mg/day; P = 0.004), lower cumulative steroid burden (158.13 ± 64.71 vs 209.24 ± 96.81 mg/day·month; P = 0.001), and had a lower proportion of IS use (47.3% vs 67.9%; P = 0.028). MSE was achieved in 56.86% in the BIO and 60.38% in the SOC group, respectively. Targeted biologics were associated with better objective muscle strength and reduced corticosteroid and IS use after MC, although no significant between-group difference was observed in MG-ADL. A substantial proportion of patients in both groups continued to have residual symptoms at 6 months.

From Mucin to Smart Medicine: Engineering Mucin-Based Biomaterials for Advanced and Responsive Drug Delivery.

Abudayah Alaa A AA

Mucin, a highly glycosylated macromolecular component of mucus, has traditionally been regarded as a biological barrier that restricts drug transport across mucosal surfaces. Growing evidence, however, has repositioned mucin as a functional and engineerable biomaterial with distinctive potential for advanced drug delivery. This review examines the evolution of mucin-based delivery systems from native mucin and bulk matrices to engineered hydrogels, hybrid materials, micro- and nanoparticles, and intrinsically glycosylated nanocarriers such as mucosomes. Particular emphasis is placed on the relationship between mucin molecular architecture and pharmaceutical functionality and on the engineering strategies used to control its material properties, including chemical modification, crosslinking, polymer hybridization, nanoscale assembly, and molecular programming. These approaches have progressively transformed mucin-based systems from passive drug reservoirs into environmentally responsive and increasingly programmable platforms capable of controlled release, molecular recognition, and on-demand therapeutic responses. Emerging applications in mucosal and ocular delivery, antimicrobial and biofilm therapy, biologics, and nucleic acid therapeutics further demonstrate the expanding pharmaceutical potential of mucin. Nevertheless, clinical translation remains constrained by source-dependent heterogeneity, variability in glycosylation and purification, batch-to-batch reproducibility, stability, sterilization, scalable manufacturing, and limited in vivo validation. Future progress will require better-defined mucin materials, standardized characterization and manufacturing, rigorous safety and efficacy assessment, and demonstration of clear therapeutic advantages over established delivery systems. Collectively, advances in mucin engineering, glycoengineering, nanotechnology, and molecular programming may enable the transition of mucin from a biological barrier component to a responsive, programmable, and clinically relevant platform for smart drug delivery.

Clinical profiles and management strategies in older adults with mild-to-moderate ulcerative colitis: a multicenter, comparative, real-world study.

Gu He H, Li Chunyan C, Liang Jie J, Tian Feng F et al.

The growing prevalence of mild-to-moderate ulcerative colitis (UC) among elderly individuals ( ≥60 years) poses unique clinical challenges due to age-related vulnerabilities, while real-world evidence on outpatient management and age-based differences remains limited. This multicenter cross-sectional study recruited 429 patients with mild-to-moderate UC from 47 inflammatory bowel disease centers. A Delphi-developed questionnaire was applied to assess clinical profiles and medication adherence. All statistical analyses were performed using R 4.5.0, with P-value < 0.05 set as the significance level. Older patients had a longer median disease duration (6.0 years vs. 4.0 years; P= 0.001) and a higher proportion with moderate disease activity (60.4% vs. 51.8%; P= 0.029) compared with non-older patients. Diagnostic efficiency, disease extent, and extraintestinal manifestations did not differ between groups. Use of 5-aminosalicylic acid (5-ASA) remained the first-line therapy in both groups, with lower corticosteroid use among older patients (8.8% vs. 16.2%; P= 0.035). Older patients reported higher satisfaction with 5-ASA across several care domains (P= 0.019). Medication adherence was similar across age groups, and adherence analysis identified switching to biologics (odds ratio [OR], 0.31; P= 0.001), 3-4 physician visits for diagnosis (OR, 0.60; P= 0.048), and greater long-term efficacy satisfaction (OR, 0.64; P= 0.049) were associated with better adherence. Older adults with mild-to-moderate UC demonstrate distinct clinical phenotypes and divergent treatment priorities. Timely therapeutic escalation, the diagnostic process, and perceived treatment effectiveness are closely associated with medication adherence. These findings highlight the need for age-adapted management strategies in elderly UC patients.